Accès ouvert · CC BY

Theranostics in Metastatic Castrate Resistant Prostate Cancer

Article scientifique 2021 Sciences de la santé Anglais

Résumé

Despite advances in the treatment of localized prostate cancer, many patients progress to metastatic castration-resistant prostate cancer with limited median survival benefits, and significant morbidity. Therefore, efforts to explore new therapeutic modalities for metastatic castration-resistant prostate cancer are urgently needed. A theranostic approach in oncology is based on the principle of imaging a particular molecular target with a diagnostic radioisotope, and then substituting it with a therapeutic isotope to treat a patient who demonstrates sufficient target expression on diagnostic images. Radioisotope pairs are usually chosen in such a way that their physical and chemical properties are similar to ensure the therapeutic agent will be distributed in the same way as the diagnostic agent. This chapter outlines the most recent advances in the use of prostate specific membrane antigen (PSMA) in theranostics with emphasis on 177Lu-PSMA, 225Ac-PSMA and 223Ra-dicloride. The clinical utility of these radioisotopes along with their limitations and future perspectives are discussed.

Citer ce document

Vorster, M. (2021). Theranostics in Metastatic Castrate Resistant Prostate Cancer. Prostate Cancer. https://doi.org/10.36255/exonpublications.prostatecancer.theranostics.2021

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 05/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Auteur(s)

Statistiques

Consultations (hors robots) : 13

Téléchargements (hors robots) : 0

Méthode de comptage